SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Abstract futuristic glowing with yellow light round sphere space star. Big data visualization. Abstract motion background shining particles, stars, magic dust flow in space. 3D rendering
Radiopharmaceuticals
Perspective Therapeutics Brings Energy to the Radiopharma World
The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and speedy speech.
June 6, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
A stack of wooden blocks with arrows pointing upwards and target board. Mission, focus, ladder of success concept.
Duchenne muscular dystrophy
Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy
Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according to BMO Capital Markets analysts.
June 5, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
Neurodegenerative disease
Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial
Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts say the outcome is unsurprising and shouldn’t affect the deal.
June 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Composite photo collage of business people hands hold checkered flags success finish vote competition isolated on painted background.
Cancer
Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax
Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about one-quarter of patients.
June 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
People walking around a convention center
Editorial
The Decadent Show of Data at ASCO25
The cancer conference overwhelms the senses and shows off the might of the pharmaceutical industry.
June 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Fantasy background for poster for tourism company. Illustration of stormy sea waves with ancient sailboat Spanish galleon and lighthouse at night. Modern print. Vector cartoon image.
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
June 2, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
A human hand and a robot hand shake hands over a white circle on a green background
Artificial intelligence
AstraZeneca Racks Up AI Partners, Seeking To Stop Cancer at All Stages
AstraZeneca has put hundreds of millions of dollars into AI deals, with an eye toward not just accelerating the development of drugs that treat cancer after it appears but also in creating diagnostics that can catch cancer earlier than current methods allow.
June 2, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Brain tumor medical poster. Cancer, metastasis or benign in the human head or in the nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain 3D vector illustration
Cancer
Jazz Is in the “Goldilocks Zone” With New Cancer Data at ASCO25
The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through Jazz Pharmaceuticals’ dealmaking over the last five years.
May 31, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Robert F Kennedy Jr speaking at the White House
Government
Court Halts HHS’ Reduction and Layoff Plans, Arguing a Lack of Authority
In an opinion issued late Thursday night, U.S. District Judge Susan Illston wrote that the president and department agency heads do not have the authority to reorganize the government without Congress’ input.
May 23, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Vaccines
Moderna Shares Fall as Combo Flu/COVID-19 Vaccine Application Pulled
After discussions with the FDA, Moderna has withdrawn its application for a combination shot, which had demonstrated efficacy in eliciting antibodies in data announced earlier this month.
May 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval; ODAC underway after chaotic planning; more.
May 21, 2025
 · 
2 min read
 · 
Heather McKenzie
Abstract colorful DNA helix held by two hands, symbolizing genetics, biology, and advancements in medical research. Conceptual art design. Concept of medicine, treatment, health care, medical science
Rare diseases
CRISPR Success in Single Baby Highlights Rare Disease ‘Crisis’
Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to the most-rare conditions, there isn’t even a pipeline.
May 20, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
3d rendering of a red and silver realistic model of a retro rocket stands crashed into a wooden desk on a blue background. Failed launch. Technological progress. Technical mistake.
Rare diseases
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial
Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few months after the FDA rebuffed the same drug in a similar indication.
May 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Close the deal by shaking hands. Art collage. Orange circle in the center.
Obesity
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with Septerna to put new discovery-stage programs into play.
May 14, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics Evaluation and Research; Bayer cuts 2,000 more employees; Eli Lilly’s Zepbound scores again; and the Galapagos story turns again.
May 14, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More